Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.69 |
| ▸ | DRD3 | P35462 | 10/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399254 | 0.81 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL2463095 | 0.81 | ADRA2C (0.60) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL3595699 | 0.80 | ADRA2C (0.55) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL24309229 | 0.79 | DRD2 (0.69) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL3399574 | 0.76 | DRD2 (0.87) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL24683684 | 0.76 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL24310707 | 0.76 | DRD2 (0.70) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL424507 | 0.75 | DRD2 (0.75) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL12359055 | 0.73 | DRD2 (0.71) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL2461864 | 0.72 | DRD2 (0.59) | DRD2DRD3HTR1ADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | DRD2 4782/4885DRD3 4637/4885HTR1A 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.